Entrectinib Patent Expiration

Entrectinib is used for treating solid tumors and cancers with specific genetic mutations. It was first introduced by Genentech Inc in its drug Rozlytrek on Aug 15, 2019.


Entrectinib Patents

Given below is the list of patents protecting Entrectinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rozlytrek US10398693 Pharmaceutical compositions and dosage forms Jul 18, 2038 Genentech Inc
Rozlytrek US11253515 Pharmaceutical compositions and dosage forms Jul 18, 2038 Genentech Inc
Rozlytrek US10738037 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May 18, 2037 Genentech Inc
Rozlytrek US11091469 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May 18, 2037 Genentech Inc
Rozlytrek US10561651 Methods for treating neuroblastoma Feb 19, 2035 Genentech Inc
Rozlytrek US10231965 Molecules for administration to ROS1 mutant cancer cells Feb 17, 2035 Genentech Inc
Rozlytrek US9085565 Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May 22, 2033 Genentech Inc
Rozlytrek US9649306 Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May 22, 2033 Genentech Inc
Rozlytrek US8299057 Substituted indazole derivatives active as kinase inhibitors Mar 01, 2029 Genentech Inc
Rozlytrek US8673893 Substituted indazole derivatives active as kinase inhibitors Jul 08, 2028 Genentech Inc
Rozlytrek US9029356 Substituted indazole derivatives active as kinase inhibitors Jul 08, 2028 Genentech Inc
Rozlytrek US9085558 Substituted indazole derivatives active as kinase inhibitors Jul 08, 2028 Genentech Inc
Rozlytrek US9255087 Substituted indazole derivatives active as kinase inhibitors Jul 08, 2028 Genentech Inc
Rozlytrek US9616059 Substituted indazole derivatives active as kinase inhibitors Jul 08, 2028 Genentech Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Entrectinib's patents.

Given below is the list recent legal activities going on the following patents of Entrectinib.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8299057
Payment of Maintenance Fee, 4th Year, Large Entity 12 Feb, 2024 US10738037
FDA Final Eligibility Letter 25 Jan, 2024 US8299057
FDA Final Eligibility Letter 25 Jan, 2024 US9029356
FDA Final Eligibility Letter 25 Jan, 2024 US8673893
FDA Final Eligibility Letter 25 Jan, 2024 US9085565
transaction for FDA Determination of Regulatory Review Period 17 Nov, 2023 US9029356
transaction for FDA Determination of Regulatory Review Period 17 Nov, 2023 US8299057
transaction for FDA Determination of Regulatory Review Period 17 Nov, 2023 US8673893
transaction for FDA Determination of Regulatory Review Period 17 Nov, 2023 US9085565


Entrectinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List